SECURITIES AND EXCHANGE COMMISSION
Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): December 14, 2004
BRISTOL-MYERS SQUIBB COMPANY
(State or Other
|(Commission File||(IRS Employer|
345 Park Avenue
New York, NY, 10154
(Address of Principal Executive Office)
Registrants telephone number, including area code: (212) 546-4000
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|Item 8.01. Other Events.|
|Item 9.01 Financial Statement and Exhibits|
Item 8.01. Other Events.
On December 14, 2004, Bristol-Myers Squibb Company announced it signed a definitive agreement to sell its Oncology Therapeutics Network (OTN) unit to One Equity Partners LLC. The transaction is expected to be completed during the first quarter of 2005, pending certain regulatory approvals. A copy of the press release is attached to this report as Exhibit 99.1.
Item 9.01 Financial Statements and Exhibits
99.1 Press Release, dated December 14, 2004, of Bristol-Myers Squibb Company.
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|Bristol-Myers Squibb Company|
Date: December 16, 2004
|By: /s/ Sandra Leung|
|Name: Sandra Leung|
|Press Release, dated December 14, 2004, of Bristol-Myers Squibb Company.|